Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07222800 | Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer | recruiting | Phase 3 | 800 | PfizerINDUSTRY | 17 | Sep 28, 2026 | clinicaltrials |
| NCT07226349 | A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 105 | BeOne MedicinesINDUSTRY | 4 | Sep 28, 2026 | clinicaltrials |
| NCT07226999 | Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer | recruiting | Phase 2 / Phase 3 | 550 | PfizerINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07277231 | A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia | recruiting | Phase 3 | 500 | BeOne MedicinesINDUSTRY | 17 | Sep 28, 2026 | clinicaltrials |
| NCT07277413 | A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors | recruiting | Phase 1 | 260 | IDEAYA BiosciencesINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07286149 | A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) | recruiting | Phase 1 / Phase 2 | 140 | Merck Sharp & Dohme LLCINDUSTRY | 11 | Sep 28, 2026 | clinicaltrials |
| NCT07293754 | An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors(RaPTR-101) | recruiting | Phase 1 / Phase 2 | 150 | Repertoire Immune MedicinesINDUSTRY | 4 | Sep 28, 2026 | clinicaltrials |
| NCT07297927 | ICG Lymphography Changes Before and After Radiotherapy in Breast Cancer Patients(ICG_prepostRT) | recruiting | — | 40 | Inah KimOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07305428 | Downstaging Unresectable Hepatocellular Carcinoma to Resectable Disease With Combined Immunotherapy and Stereotactic Beamed Radiotherapy: a Pilot Study | recruiting | N/A | 30 | The University of Hong KongOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07326566 | Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII | recruiting | Phase 2 | 162 | Black Diamond Therapeutics, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07346157 | Liothyronine in Combination With BIT Regimen for Medulloblastoma With or Without Minimal Residual Disease(PNOC044) | recruiting | Phase 1 / Phase 2 | 69 | Sabine Mueller, MD, PhDOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07372079 | Neoadjuvant Therapy for Early Triple-Negative Breast Cancer: A Response-Guided Approach Using Iparomlimab and Tuvonralimab Injection in Combination With Chemotherapy | recruiting | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07380646 | the Efficacy of Leucogen in Preventing the Risk of Ribociclib-Associated Neutropenia in Early Breast Cancer | recruiting | Phase 2 | 97 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07391774 | Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial | recruiting | Phase 3 | 1,978 | National Cancer Institute (NCI)NIH | 2 | Sep 28, 2026 | clinicaltrials |
| NCT07392892 | Symbiotic-GI-16: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer | recruiting | Phase 2 / Phase 3 | 840 | PfizerINDUSTRY | 10 | Sep 28, 2026 | clinicaltrials |
| NCT07414836 | A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 84 | BeOne MedicinesINDUSTRY | 4 | Sep 28, 2026 | clinicaltrials |
| NCT07416188 | Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 40 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07421700 | Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 132 | PfizerINDUSTRY | 6 | Sep 28, 2026 | clinicaltrials |
| NCT07432178 | CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer(Cinnamon) | recruiting | Phase 3 | 2,288 | Fudan UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07439653 | A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma | recruiting | Phase 1 / Phase 2 | 155 | TORL Biotherapeutics, LLCINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07460440 | SPARC - Screening for Lung Cancer With Platelets Via an AI-enabled RNA-based Classifier(SPARC) | recruiting | — | 240 | University of UtahOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07498907 | Disitamab Vedotin Plus Radiotherapy for Adjuvant Treatment of HER2-Expressing Cisplatin-Ineligible Upper Tract Urothelial Carcinoma(LUXUS41) | recruiting | Phase 3 | 192 | Peking University First HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07513376 | A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)(INTerpath-014) | recruiting | Phase 3 | 876 | Merck Sharp & Dohme LLCINDUSTRY | 18 | Sep 28, 2026 | clinicaltrials |
| NCT07515651 | Molecular Imaging Informed Radiation Dose Escalation to Sites of Recurrent Disease and De-escalation to Uninvolved Areas in Salvage Radiotherapy Using SBRT for Prostate Cancer to Reduce Treatment Toxicity(MIDAS-SBRT) | not yet recruiting | Phase 2 | 50 | University Health Network, TorontoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07519655 | Phase 1 Study of PF-08046033 in Advanced Solid Tumors | recruiting | Phase 1 | 250 | PfizerINDUSTRY | 5 | Sep 28, 2026 | clinicaltrials |
| NCT07543757 | Prostate Cancer Risk Identification in a Multi-Ethnic Cohort: a Prospective US-based Multi-center Validation Study of Proclarix(PRIME) | recruiting | — | 500 | Sequenom, Inc.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07553234 | Study to Understand Relationship Between Gut Health and Toxicities of Hormonal Breast Cancer Treatment(GEMMA) | recruiting | N/A | 20 | University of ChicagoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07578649 | Symbiotic-GYN-18: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Advanced or Recurrent MMR-proficient Endometrial Cancer | not yet recruiting | Phase 3 | 600 | PfizerINDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT07594106 | REGN15505 (PSMAx4-1BB) Alone or in Combination With Cemiplimab or REGN4336 (PSMAxCD3) in Adult Patients With Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma | recruiting | Phase 1 / Phase 2 | 265 | Regeneron PharmaceuticalsINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07601334 | Safety and Activity of HF50 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 45 | HighField Biopharmaceuticals CorporationINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07621718 | Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )(RASolute 305) | recruiting | Phase 3 | 670 | Revolution Medicines, Inc.INDUSTRY | 2 | Sep 28, 2026 | clinicaltrials |
| NCT07660939 | GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders | recruiting | Phase 1 | 50 | Peking University First HospitalOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07685717 | Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia | recruiting | Phase 2 | 50 | Jennifer WoyachOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07691762 | A Study of TACE in Combination With SHR-8068, Adebrelimab, and Bevacizumab Versus TACE in Participants With Incurable Hepatocellular Carcinoma | not yet recruiting | Phase 3 | 690 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07698106 | Enhancing ICB Efficacy Through IL-1 Inhibition in TNBC | not yet recruiting | Phase 1 / Phase 2 | 60 | University Health Network, TorontoOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07698366 | Breast Ultrasound Screening in Elderly Women: A Multicenter Cluster Randomized Trial | recruiting | N/A | 80,000 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07704476 | EXERT-BC Protein: Protein Supplementation to Improve Body Composition After Treatment for Breast Cancer | recruiting | N/A | 40 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07722611 | A Clinical Trial of Bomedemstat in Participants With Polycythemia Vera (MK-3543-025) | recruiting | Phase 2 / Phase 3 | 380 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07733024 | Comparing DLL3 PET/CT to Standard Scans in Neuroendocrine Cancer(DSC-NEC) | recruiting | Phase 2 | 200 | Tingting YuanOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07733180 | A Study Investigating Alternate Schedules of Tislelizumab Plus Chemotherapy in Japanese Patients With First-line Advanced ESCC | recruiting | Phase 2 | 30 | BeOne MedicinesINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07737314 | Tele-HOPE: A Telehealth Pharmacist Opioid Patient Education Pilot Study | not yet recruiting | N/A | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07740317 | Neurocognitive Trajectories After BCMA CAR-T(CAR-T Cog) | not yet recruiting | — | 50 | Wake Forest University Health SciencesOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07836933 | Cancer Oriented Understanding and Navigation Via Supportive and Educational Language Models (COUNSEL) | not yet recruiting | N/A | 50 | University of California, San FranciscoOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07839247 | Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSL | recruiting | Phase 2 | 33 | Xiaohui RenOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07842679 | Cognitive Impairment in Older Adults With Hematologic Malignancies | not yet recruiting | — | 120 | Assiut UniversityOTHER | 0 | Sep 28, 2026 | clinicaltrials |
| NCT07843303 | Trastuzumab Rezetecan Plus Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer: A Phase II,Multicenter, Single-Arm Study | not yet recruiting | Phase 2 | 53 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07843433 | ImprovINg the TIMEly Diagnosis and Treatment of Cancer and Cardio-metabolic Diseases in People With Mental Disorders: Reducing Health Disparities Through Integrated Care(IN-TIME) | not yet recruiting | — | 120 | IRCCS San RaffaeleOTHER | 0 | Sep 28, 2026 | clinicaltrials |
Data updated 3 days agoSource updated Sep 28, 2026source: clinicaltrials